Home › Trial NCT05996484
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
- Trial IDNCT05996484
- StatusUnknown
- PhasePhase 2
- Study typeInterventional
- SponsorNanfang Hospital, Southern Medical University
- Enrollment25
- Start date2023-09
- ConditionsEsophageal Carcinoma · Neoadjuvant Therapy
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.